JP6851819B2 - Capillary increase agent - Google Patents
Capillary increase agent Download PDFInfo
- Publication number
- JP6851819B2 JP6851819B2 JP2016255435A JP2016255435A JP6851819B2 JP 6851819 B2 JP6851819 B2 JP 6851819B2 JP 2016255435 A JP2016255435 A JP 2016255435A JP 2016255435 A JP2016255435 A JP 2016255435A JP 6851819 B2 JP6851819 B2 JP 6851819B2
- Authority
- JP
- Japan
- Prior art keywords
- capillaries
- capillary
- ingestion
- aging
- skin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000001965 increasing effect Effects 0.000 claims description 9
- 206010046996 Varicose vein Diseases 0.000 claims description 4
- 239000004480 active ingredient Substances 0.000 claims description 4
- 230000003712 anti-aging effect Effects 0.000 claims description 4
- 230000008961 swelling Effects 0.000 claims description 4
- 208000027185 varicose disease Diseases 0.000 claims description 4
- 241000588912 Pantoea agglomerans Species 0.000 claims description 3
- 230000037406 food intake Effects 0.000 description 10
- 239000002158 endotoxin Substances 0.000 description 7
- 229920006008 lipopolysaccharide Polymers 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 101100481408 Danio rerio tie2 gene Proteins 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 101100481410 Mus musculus Tek gene Proteins 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 235000008534 Capsicum annuum var annuum Nutrition 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- 235000019510 Long pepper Nutrition 0.000 description 2
- 240000003455 Piper longum Species 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 230000006866 deterioration Effects 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- KGXUEPOHGFWQKF-ZCXUNETKSA-N flutianil Chemical compound COC1=CC=CC=C1N(CCS\1)C/1=C(C#N)/SC1=CC(C(F)(F)F)=CC=C1F KGXUEPOHGFWQKF-ZCXUNETKSA-N 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000009759 skin aging Effects 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- 244000223760 Cinnamomum zeylanicum Species 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 238000000585 Mann–Whitney U test Methods 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 239000002870 angiogenesis inducing agent Substances 0.000 description 1
- 238000003287 bathing Methods 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000017803 cinnamon Nutrition 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 210000004905 finger nail Anatomy 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 210000000282 nail Anatomy 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Landscapes
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
本発明は、毛細血管の数を増加させる毛細血管増加剤に関する。 The present invention relates to a capillary increasing agent that increases the number of capillaries.
毛細血管は、末梢部位まで網目状にはりめぐらされている細い血管であり、体の隅々まで栄養、酸素、ホルモン等を運ぶ役割とともに、水分、体温の調節にも関与している。このため毛細血管の健全性は健康や美容にも影響する（非特許文献１）。毛細血管は、直径５〜１０ミクロンの細さであるため、老廃物により詰まりやすく、さらに加齢とともに減少したり、毛細血管壁がもろくなって血液が漏れ出ることもある。毛細血管の働きが悪いと、冷え症やほてりを感じたり、むくみや静脈瘤、肌の老化の原因ともなる（非特許文献２）。 Capillaries are small blood vessels that are laid out in a mesh pattern to peripheral parts, and are involved in the regulation of water and body temperature as well as the role of transporting nutrients, oxygen, hormones, etc. to every corner of the body. Therefore, the soundness of capillaries also affects health and beauty (Non-Patent Document 1). Since the capillaries are as thin as 5 to 10 microns in diameter, they are easily clogged with waste products, and may decrease with age, or the walls of the capillaries may become brittle and blood may leak out. If the capillaries do not work well, it may cause poor circulation, burning, swelling, varicose veins, and skin aging (Non-Patent Document 2).
毛細血管の働きを正常化するにあたり、ウオーキング、スキップ、かかとの上げ下ろしなどの適度な運度や、ふくらはぎのマッサージ、入浴等によって血流速度をあげることが効果があるとされている（非特許文献１）。また、血管新生因子の受容体であるTie2（Tyrosine Kinase with Ig and EGF Homology Domain 2）を活性化させることが、劣化した毛細血管壁を修復して丈夫にするために有効であるとされている（非特許文献３）。Tie2増加作用のある物質としては、ケイヒ（シナモン）、ヒハツが知られている（特許文献１、非特許文献４）。 In order to normalize the function of capillaries, it is said that it is effective to increase the blood flow rate by walking, skipping, raising and lowering the heel, etc., and by massaging the calf, bathing, etc. (Non-patent documents) 1). In addition, activation of Tie2 (Tyrosine Kinase with Ig and EGF Homology Domain 2), which is a receptor for angiogenic factors, is said to be effective in repairing and strengthening deteriorated capillary walls. (Non-Patent Document 3). Keihi (cinnamon) and long pepper are known as substances having a Tie2 increasing action (Patent Document 1, Non-Patent Document 4).
一方、毛細血管の血流速度をあげたり劣化修復をすることとは別に、加齢とともに数が減少すると言われる毛細血管の数を増やすことができれば、健康上及び美容上のトラブルの予防と改善に効果があると考えられるが、毛細血管の数を増やす因子についてはこれまで知られていない。 On the other hand, if the number of capillaries, which is said to decrease with age, can be increased apart from increasing the blood flow velocity of capillaries and repairing deterioration, prevention and improvement of health and cosmetic problems can be achieved. However, the factors that increase the number of capillaries have not been known so far.
本発明は、上記問題点に鑑み、毛細血管の数を増やすことで毛細血管の健全性を高める毛細血管増加剤を提供することを目的とする。 In view of the above problems, an object of the present invention is to provide a capillary blood vessel increasing agent that enhances the soundness of capillaries by increasing the number of capillaries.
本発明の毛細血管増加剤は、パントエア・アグロメランス由来ＬＰＳ（リポ多糖）を有効成分として含有し、冷え感、むくみ若しくは静脈瘤に対して、又は、肌のアンチエイジングのために、経口投与するものであることを特徴とする。 The capillary increasing agent of the present invention contains LPS (lipopolysaccharide) derived from Pantoea agglomerans as an active ingredient and is orally administered for cold feeling, swelling or varicose veins, or for skin anti-aging. It is characterized by being.
本発明によれば、毛細血管の数が増える。したがって、体の隅々まで栄養素や酸素が行き渡り、冷え感、むくみ、静脈瘤の予防・改善のほか、肌のアンチエイジングの効果が期待できる。 According to the present invention, the number of capillaries increases. Therefore, nutrients and oxygen are distributed to every corner of the body, and in addition to prevention and improvement of coldness, swelling, and varicose veins, anti-aging effects on the skin can be expected.
以下、添付図面を参照しながら本発明を実施するための形態について詳細に説明する。 Hereinafter, embodiments for carrying out the present invention will be described in detail with reference to the accompanying drawings.
下記のように、ＬＰＳを有効成分として含む錠剤、または含まないプラセボ錠剤のいずれかを、ダブルブラインドで３か月間摂取する前後において、爪下の毛細血管の顕微鏡写真を撮影し、一定の視野内における毛細血管の本数を比較した。測定は摂取前と３か月摂取後の２度行われた。図１は、測定結果を、摂取前の指先の毛細血管数を１とする相対値で示す。統計解析はマンホイットニーのＵ検定を使った。
As shown below, before and after taking either a tablet containing LPS as an active ingredient or a placebo tablet not containing LPS in a double blind for 3 months, micrographs of the capillaries under the nails were taken and within a certain field of view. The number of capillaries in the above was compared. Measurements were taken twice, before and after 3 months of ingestion. FIG. 1 shows the measurement result as a relative value with the number of capillaries of the fingertip before ingestion being 1. The statistical analysis used the Mann-Whitney U test.
・対象者：年齢が２０歳以上７４歳以下の男女で、健康診断で測定する血液マーカー数値が正常から境界域に入る健常人５２名（女性３４人、男性１８人）。
・試験品：パントエア・アグロメランス由来ＬＰＳを２５０μｇ配合した８ｍｍ径、２００ｍｇの錠剤型サプリメント（デキストリン、還元麦芽糖、セルロース、ステアリン酸カルシウムからなる）。対照品は、ＬＰＳをデキストリンに置き換えたサプリメント。
・摂取方法：１日１回、原則夕食前に２錠を摂取
・摂取期間：３か月
・試験デザイン：ランダム化並行群間ダブルブラインド試験
・調査項目：左薬指の爪下の毛細血管の密度（一定視野内の毛細血管数）
・調査方法：毛細血管観察装置（あっと株式会社）による顕微鏡画像のビデオ撮影
-Subjects: 52 healthy subjects (34 females and 18 males) who are between the ages of 20 and 74 and whose blood marker values measured in the health examination fall from normal to the borderline.
-Test product: An 8 mm diameter, 200 mg tablet-type supplement containing 250 μg of LPS derived from Pantoea agglomerans (consisting of dextrin, reduced maltose, cellulose, and calcium stearate). The control product is a supplement in which LPS is replaced with dextrin.
・ Ingestion method: Take 2 tablets once a day, in principle, before dinner ・ Ingestion period: 3 months ・ Test design: Random parallel group double-blind test ・ Survey item: Density of capillaries under the fingernail of the left ring finger (Number of capillaries in a constant field of view)
・ Survey method: Video recording of microscopic images using a capillary observation device (Atto Co., Ltd.)
その結果、ＬＰＳを有効成分として含む錠剤を摂取したグループは、プラセボ錠剤を接種したグループと比べて、毛細血管数が有意差をもって（Ｐ＝０．０３６）増加したことが認められた。
As a result, it was found that the number of capillaries increased significantly (P = 0.036) in the group ingesting the tablet containing LPS as an active ingredient as compared with the group inoculated with the placebo tablet.
実施例１と同様のダブルブラインド試験において、冷え感について、視覚的アナログ尺度（visual analogue scale=ＶＡＳ）を用いる自己評価にて、摂取前と摂取後の調査を行った。その結果、冷えを感じる人数が、試験品群では摂取前２１人から摂取後１６人に変化した。対照品群では摂取前１９人、摂取後１７人であった。このことから、試験品群には冷えを改善する効果があることが示された。 In the same double-blind test as in Example 1, the feeling of coldness was investigated before and after ingestion by self-evaluation using a visual analog scale (VAS). As a result, the number of people who felt cold changed from 21 before ingestion to 16 after ingestion in the test product group. In the control group, there were 19 before ingestion and 17 after ingestion. From this, it was shown that the test product group has an effect of improving coldness.
なお、本発明は上記実施例に限定されるものではない。
The present invention is not limited to the above examples.
Claims (1)
A capillary increasing agent containing LPS derived from Pantoea agglomerans as an active ingredient and administered orally for a feeling of coldness, swelling or varicose veins, or for anti-aging of the skin.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2016255435A JP6851819B2 (en) | 2016-12-28 | 2016-12-28 | Capillary increase agent |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2016255435A JP6851819B2 (en) | 2016-12-28 | 2016-12-28 | Capillary increase agent |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018104389A JP2018104389A (en) | 2018-07-05 |
| JP6851819B2 true JP6851819B2 (en) | 2021-03-31 |
Family
ID=62787126
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016255435A Active JP6851819B2 (en) | 2016-12-28 | 2016-12-28 | Capillary increase agent |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP6851819B2 (en) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6452725A (en) * | 1987-08-24 | 1989-02-28 | Nippon Kayaku Kk | New formation agent for blood vessel |
| US7462593B2 (en) * | 2002-11-07 | 2008-12-09 | Us Gov Health & Human Serv | Compositions and methods for promoting angiogenesis |
| JP6234003B2 (en) * | 2012-01-13 | 2017-11-22 | 小林製薬株式会社 | VEGF production promoter |
-
2016
- 2016-12-28 JP JP2016255435A patent/JP6851819B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2018104389A (en) | 2018-07-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Buvat et al. | Dapoxetine for the treatment of premature ejaculation: results from a randomized, double-blind, placebo-controlled phase 3 trial in 22 countries | |
| Machado et al. | Assessment of the variation of skin barrier function with anatomic site, age, gender and ethnicity | |
| Grassi et al. | Flavanol-rich chocolate acutely improves arterial function and working memory performance counteracting the effects of sleep deprivation in healthy individuals | |
| Pena Ferreira et al. | Efficacy of anti‐wrinkle products in skin surface appearance: a comparative study using non‐invasive methods | |
| Nuttall | Interpreting hair mercury levels in individual patients | |
| Fuchs et al. | Impact of flavonoid-rich black tea and beetroot juice on postprandial peripheral vascular resistance and glucose homeostasis in obese, insulin-resistant men: a randomized controlled trial | |
| Uchiyama et al. | Oral intake of glucosylceramide improves relatively higher level of transepidermal water loss in mice and healthy human subjects | |
| Gijsman et al. | Pharmacokinetic and pharmacodynamic profile of oral and intravenous meta-chlorophenylpiperazine in healthy volunteers | |
| Green et al. | Studies on the effect of MDMA (‘ecstasy’) on the body temperature of rats housed at different ambient room temperatures | |
| Yue et al. | Efficacy of dapoxetine for the treatment of premature ejaculation: a meta-analysis of randomized clinical trials on intravaginal ejaculatory latency time, patient-reported outcomes, and adverse events | |
| Champatisingh et al. | Anticataleptic and antiepileptic activity of ethanolic extract of leaves of Mucuna pruriens: A study on role of dopaminergic system in epilepsy in albino rats | |
| Minami et al. | Suppression of reward-induced dopamine release in the nucleus accumbens in animal models of depression: Differential responses to drug treatment | |
| Garrigue et al. | Evaluation of the moisturizer Pédimed® in the foot care of diabetic patients | |
| Dogan et al. | Algorithms to measure carotid intima–media thickness in trials: a comparison of reproducibility, rate of progression and treatment effect | |
| Coelho-Junior et al. | Age-and gender-related changes in physical function in community-dwelling Brazilian adults aged 50 to 102 years | |
| Kanti et al. | Postnatal maturation of skin barrier function in premature infants | |
| Murdan et al. | An assessment of the human nail plate pH | |
| Kwan et al. | Vascular effects of Siberian ginseng (Eleutherococcus senticosus): endothelium-dependent NO-and EDHF-mediated relaxation depending on vessel size | |
| JP6851819B2 (en) | Capillary increase agent | |
| O’Driscoll et al. | One year of Isometric exercise training for blood pressure management in men: a prospective randomized controlled study | |
| Alsufyani et al. | Gender differences in the effects of cathinone and the interaction with caffeine on temperature and locomotor activity in the rat | |
| Mohamed et al. | Escitalopram for comorbid depression and anxiety in elderly patients: a 12-week, open-label, flexible-dose, pilot trial | |
| Sharma et al. | Unilateral linear punctate palmoplantar keratoderma | |
| Ramesh et al. | Cutaneous signs of piety | |
| Lewis et al. | The effect of time-of-day and sympathetic α1-blockade on orthostatic tolerance |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20190911 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200826 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20201021 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20210303 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20210310 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6851819 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |